This article is part of our ongoing coverage of Renal Week 2009. Click here for a complete list of our Renal Week Live articles.
Key Points
- Cinacalcet showed long-term efficacy in reducing serum parathyroid hormone (PTH) and calcium levels in renal transplant patients with refractory tertiary hyperparathyroidism.
- Serum PTH decreased significantly from a mean of 236 pmol/L at baseline to 180 at 12 months.
- Serum calcium decreased significantly from 10.8 mg/day to 10.0.
Cinacalcet showed long-term efficacy in reducing serum parathyroid hormone (PTH) and calcium levels in renal transplant patients with refractory tertiary hyperparathyroidism, according to a study presented at ASN’s Renal Week 2009.
Continue Reading
Dimitrios-Anestis Moutzouris, MD, and colleagues at Evangelismos General Hospital in Athens, Greece, followed 24 renal transplant recipients (17 male, 7 female) who had stable renal function at least three months before administration of cinacalcet. Seventeen patients were on cyclosporine, five were on tacrolimus, and two were on everolimus. The patients had a mean age of 56 years.
Clinicians started patients on cinacalcet a mean 27 months after transplantation because of hypercalcemia and hyperparathyroidism that was refractory to standard medical treatment (mainly vitamin D analogues). The usual dose of cinacalcet was 30-60 mg per day.
Serum PTH decreased significantly from a mean of 236 pmol/L at baseline to 180 at 12 months. During that same period, serum calcium decreased significantly from 10.8 mg/day to 10.0, the investigators reported. Renal function and serum phosphorus levels at 12 months were not significantly different from baseline.
